A Bedside Light-Touch Test at the Index Finger Predicts 6-Month Whiplash Outcome
Fundaun and colleagues followed 129 acute whiplash patients with a battery of clinical exams, quantitative sensory testing, skin biopsy, and serum biomarkers. The bedside test that mattered was simple: light-touch sensitivity at the index finger. Hypoaesthesia at that single point in the acute phase predicted upper-quadrant pain at six months. Serum neurofilament light chain was elevated in the acute injury group, suggesting axonal injury. Whiplash is not only a soft-tissue diagnosis.
Key Points
- Fundaun and colleagues prospectively followed 129 patients with acute whiplash-associated disorder Grade II (median age 36, 58 percent female) plus 36 matched healthy controls. Sixty-six patients completed paired six-month follow-up assessments.
- The patient battery included clinical neurological exam, quantitative sensory testing, skin biopsy, and serum biomarkers including neurofilament light chain.
- Bedside hypoaesthesia at the index finger was the strongest single clinical predictor of upper-quadrant pain at six months. Multivariable linear regression r-squared was 0.13 (P = 0.02). Modest variance explained but a clinically usable signal.
- Quantitative sensory testing abnormalities (warm detection threshold, thermal sensory limen, mechanical detection) persisted at six-month follow-up at moderate effect sizes (Cohen d greater than 0.44).
- Serum neurofilament light chain was elevated in the acute whiplash group versus healthy controls (Cohen d -0.52, 95 percent confidence interval -0.94 to -0.10). Neurofilament light chain is a marker of axonal injury.
- The findings argue that whiplash carries a measurable nerve-injury component in a subset of patients. The standard musculoskeletal-only framing of whiplash-associated disorder is incomplete.
- This is one prospective cohort. External validation in independent cohorts is needed before integrating into prognostic prediction tools like WhipPredict.
Whiplash has historically been classified as a soft-tissue injury: stretched muscles, irritated facet joints, sometimes a strained ligament. The thinking has been that the imaging is normal because the tissue at fault is too small to see. The Fundaun group asked a different question: what if some whiplash patients also have measurable nerve injury that has been missed because no one was looking for it?
They followed 129 people with acute whiplash for six months, comparing them to 36 healthy controls. Each patient got a careful neurological exam, quantitative sensory testing, a small skin biopsy to look at small nerve fibers directly, and a blood test for neurofilament light chain (a marker that goes up in the blood when nerve axons are damaged).
The clinical finding that mattered most was simple. A standard light-touch test at the tip of the index finger. If that area was less sensitive than expected at the acute visit, the patient was more likely to still have arm or shoulder pain six months later.
Why is the index finger relevant for a neck injury? The C6 and C7 nerve roots are commonly affected by acceleration-deceleration injuries to the cervical spine, and those nerve roots feed sensation to the lateral hand and the index finger specifically. Light-touch loss at the index finger is a fingerprint of upper cervical nerve-root involvement.
The blood marker added independent evidence that some of these injuries involve actual axonal damage, not only muscle and ligament. The translation: whiplash is a heterogeneous diagnosis. Some patients have soft-tissue strain that resolves on its own. Others have nerve injury that needs specific recognition and a longer recovery arc.
Why This Paper Matters
Whiplash-associated disorder (WAD) is a common diagnosis that has resisted prognostic precision for decades. Most patients recover within three months. A meaningful subset, often quoted as 30 to 50 percent depending on the cohort, develops persistent symptoms beyond six months. The clinical question at the acute visit has always been: which patients are which?
The dominant validated prognostic tool in the space is WhipPredict, which uses the Neck Disability Index, post-traumatic hyperarousal, and age to estimate recovery probability. WhipPredict is a psychosocial-and-symptom prediction model. It does not include a biological marker.
The Fundaun cohort adds a biological layer. The finding that bedside hypoaesthesia at the index finger predicts upper-quadrant pain at six months is novel for two reasons. First, it implicates a specific nerve-root distribution (C6 in the canonical map) rather than a diffuse soft-tissue process. Second, it is a free, equipment-light, quick clinical test that can be done at the acute visit by any clinician.
The blood biomarker finding (elevated neurofilament light chain) is independent corroboration that the underlying biology in some patients includes axonal injury. Neurofilament light chain has been validated in other neurological conditions including traumatic brain injury, multiple sclerosis, and amyotrophic lateral sclerosis as a marker of axonal damage.
What the Study Did
The Fundaun group prospectively enrolled 129 patients with acute WAD II within four weeks of motor vehicle injury, plus 36 healthy controls matched for age and sex. The acute assessment included a structured neurological exam (sensation to light touch, pinprick, vibration; motor strength; deep tendon reflexes), full quantitative sensory testing per the German Research Network on Neuropathic Pain protocol, skin biopsy at the calf for intraepidermal nerve fiber density assessment, and serum neurofilament light chain measurement.
Outcome measures at six-month follow-up included the Neck Disability Index, the Brief Pain Inventory, and a structured re-assessment of the original clinical and quantitative sensory testing battery. Sixty-six of the 129 patients completed the paired six-month assessment (51 percent retention).
Statistical analysis used multivariable linear regression with the six-month upper-quadrant pain score as the dependent variable and acute clinical, quantitative sensory testing, and serum biomarker measures as candidate predictors. Effect sizes were reported as standardized regression coefficients and Cohen d.
What the Study Found
The clinical exam predictor that survived multivariable adjustment was light-touch hypoaesthesia at the index finger. This single bedside test explained 13 percent of variance in upper-quadrant pain at six months (r-squared 0.13, P = 0.02). For interpretive scale: a single clinical predictor explaining 10 to 15 percent of variance in a complex chronic pain outcome is a meaningful signal in this literature.
Quantitative sensory testing abnormalities persisted at follow-up. Warm detection threshold, thermal sensory limen, and mechanical detection threshold all showed effect sizes greater than 0.44 versus controls. The persistence indicates that the sensory abnormalities present in the acute phase are not transient sensitization that resolves with the acute injury. They are a stable signal.
Serum neurofilament light chain was elevated in the acute whiplash group versus healthy controls at Cohen d -0.52 (95 percent CI -0.94 to -0.10). The negative effect size in this convention reflects that controls had higher inverse-scaled values; the substantive interpretation is that the patient group had elevated neurofilament light chain consistent with axonal injury.
Skin biopsy results showed reduced intraepidermal nerve fiber density in a subset of patients. The reduced density correlated with quantitative sensory testing findings, supporting the small-fiber-pathology interpretation.
How to Use the Index-Finger Test
The bedside test is straightforward. The clinician uses a standard light-touch tool (a cotton wisp, a 10-gram monofilament, or a soft brush) at the dorsal aspect of the index finger pad on both sides. The patient closes their eyes. The clinician applies the stimulus and asks whether the patient can feel it and whether it feels equal on both sides.
A positive finding is reduced sensation on the symptomatic side compared to the asymptomatic side, or a clear report of "I don't feel that as much" at the index finger. A more rigorous approach uses calibrated monofilaments to quantify the threshold.
If positive, the Fundaun data suggest a higher probability of upper-quadrant pain persisting at six months. The test does not rule out persistence in patients with normal sensation; it identifies a higher-risk subgroup.
The clinical value is in expectation-setting and treatment-intensity calibration. A patient with bedside hypoaesthesia at the index finger should be counseled that recovery may take longer than the average WAD II course, that more frequent re-assessment is appropriate, and that referral for advanced imaging or neurology consultation should have a lower threshold if symptoms persist.
Limitations and Caveats
Sample size and retention. 129 enrolled, 66 paired six-month assessments (51 percent retention). The retention rate is typical for chronic pain prospective cohorts but introduces attrition bias. Patients with worse outcomes may be over-represented or under-represented in the follow-up sample.
Single-cohort study without external validation. The index-finger hypoaesthesia finding has not been replicated in an independent dataset. External validation in a separate cohort is the appropriate next step before integrating this predictor into validated prognostic tools like WhipPredict.
Variance explained is modest (r-squared 0.13). The finding is statistically significant and clinically informative as a screening signal, but it does not approach the predictive precision needed to make individual-patient prognostic statements with high confidence.
The bedside test was performed by trained examiners in a research setting. Inter-rater reliability for light-touch testing in routine clinical practice is lower than in controlled studies. Generalization to community practice may attenuate the signal.
Neurofilament light chain elevation is consistent with axonal injury but is not specific to cervical nerve root pathology. Confounders including comorbid systemic conditions and inflammatory states have not been ruled out in this dataset.
The findings challenge the standard musculoskeletal-only framing of WAD II but do not establish the prevalence of frank nerve injury in the broader whiplash population. The cohort is enriched for clinical research participation and may not represent average clinical presentations.
None of these limits invalidate the headline. They define the size of the claim that can be honestly made: in a prospective cohort of acute WAD II patients, bedside light-touch hypoaesthesia at the index finger at the acute visit predicted upper-quadrant pain persistence at six months at a clinically meaningful effect size. Replication in an independent cohort is the appropriate next step before incorporating into validated prognostic tools.
Clinical Context
Whiplash prognostic research has been dominated by psychosocial-and-symptom predictors for two decades. The biological component of the recovery picture has been understudied largely because the imaging modalities available at the time of injury (plain films, occasionally CT, rarely MRI) have not consistently shown structural abnormalities that correlate with outcome.
The Fundaun framework opens a different access point: clinical neurology done carefully at the acute visit, plus a circulating biomarker that is now widely available in research labs and increasingly in clinical settings. The combination is plausibly cheap and rapidly translatable.
The clinical implication, if the finding replicates, is a shift in how acute whiplash is triaged. Patients with bedside hypoaesthesia at the index finger become a defined higher-risk subgroup who warrant closer monitoring, structured re-assessment, and a lower threshold for advanced workup. Patients without the finding are the lower-risk group for whom standard WAD care is likely appropriate.
The finding does not change first-line treatment. Conservative care remains the appropriate starting point for WAD II in both subgroups. What it changes is the prognostic conversation and the calibration of follow-up intensity.
One prospective cohort of 129 acute whiplash patients with paired six-month follow-up. One bedside test (light-touch sensitivity at the index finger) at the acute visit predicts upper-quadrant pain at six months at a clinically meaningful effect size. One blood biomarker (neurofilament light chain) corroborates underlying axonal injury in a subset. The standard musculoskeletal-only framing of whiplash is incomplete. Replication in an independent cohort is the next required step before this signal moves into validated prognostic tools.
Editorial Disclosure
The Forward Review is editorial commentary, not peer reviewed. Written by Jason Forward, DC, a licensed chiropractor at Vanguard Chiropractic in Tulsa, Oklahoma. Commentary reflects clinical interpretation of published research and does not represent the views of the original study authors, the journal Brain, or any institution.
Conflict of interest: No financial relationships with the cited authors, the publisher, or any party to this work.
Scope of practice note: Neurological diagnosis and the interpretation of serum biomarkers are outside chiropractic scope of practice. Discussion of these findings in this commentary refers to published research and is not a representation that chiropractic care includes biomarker assessment.
Corrections policy: Errors are corrected with a dated correction notice appended to the article. Original text remains accessible via revision history.
Level of evidence: Single prospective cohort study, n=129 (66 with paired follow-up). Hypothesis-generating evidence on a novel bedside prognostic test. Independent replication required before clinical adoption.
- Nystagmus Does Not Belong to Vasovagal Syncope. If You Have Both, Something Is Unexplained.Forward Rev. 2026;1(2)
- Which Neck Exercise Actually Works? A 2026 Network Meta-AnalysisForward Rev. 2026;1(2)
- Why Treating the Mid-Back Helps the Shoulder: 2026 Thoracic Manual Therapy EvidenceForward Rev. 2026;1(2)
- Can Your Neck Cause Dizziness? What the 2025 Evidence ShowsForward Rev. 2026;1(2)
View Vol. I, No. i and the full archive